OXYMORPHONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H19NO4
Molecular Weight	301.3371
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@]3(O)CCC4=O)=CC=C5O

InChI

InChIKey=UQCNKQCJZOAFTQ-ISWURRPUSA-N

InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C17H19NO4
Molecular Weight	301.3371
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011707s036lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021611lbl.pdf | https://www.drugs.com/pro/oxymorphone.html

Oxymorphone is an analgesic that is FDA approved for the treatment of moderate to severe pain. It is also indicated for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction. Oxymorphone (brand names Opana, Numorphan, Numorphone) is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Adverse reactions (≥ 2% of patients): seen with the immediate release tablet formulation Nausea, pyrexia, somnolence, vomiting, pruritus, headache, dizziness, constipation, and confusion. Concomitant use with serotonergic drugs may result in serotonin syndrome. Avoid use of mixed agonist/antagonist and partial agonist opioid analgesics with Opana because they may reduce analgesic effect of Opana or precipitate withdrawal symptoms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mu opioid receptor 221 Target ID: CHEMBL233 Sources: Sinatra R.S., Jahr J.S., Watkins-Pitchford J.M.. (2010) 'The Essence of Analgesia and Analgesics', p.124 Retrieved from \| https://books.google.ru/books?id=ZwPIjKg0XukC	Agonist 2662	0.93 nM [Ki]
Delta opioid receptor 78 Target ID: CHEMBL236 Sources: Sinatra R.S., Jahr J.S., Watkins-Pitchford J.M.. (2010) 'The Essence of Analgesia and Analgesics', p.124 Retrieved from \| https://books.google.ru/books?id=ZwPIjKg0XukC	Agonist 2662	80.5 nM [Ki]
Kappa opioid receptor 108 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24919067	Agonist 2662	61.6 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 608 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011707s036lbl.pdf	Palliative		Approved 8360	OPANA Approved Use Enter section text here - OPANA ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. (1) - Not intended for use as an as needed analgesic. Not indicated in the immediate post-operative period or if the pain is mild or not expected to persist for an extended period of time. (1), 1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Limitations of Usage OPANA ER is not intended for use as an as needed analgesic. OPANA ER is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines). Launch Date -3.39292815E11
Anxiety 266 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011707s036lbl.pdf	Palliative		Approved 8360	OPANA Approved Use Enter section text here - OPANA ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. (1) - Not intended for use as an as needed analgesic. Not indicated in the immediate post-operative period or if the pain is mild or not expected to persist for an extended period of time. (1), 1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. Limitations of Usage OPANA ER is not intended for use as an as needed analgesic. OPANA ER is not indicated for pain in the immediate post-operative period if the pain is mild, or not expected to persist for an extended period of time. OPANA ER is only indicated for post-operative use if the patient is already receiving the drug prior to surgery or if the post-operative pain is expected to be moderate or severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines). Launch Date -3.39292815E11

C_max

Value	Dose	Analyte	Population
1.21 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2.54 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.47 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.59 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.27 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
17.81 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
19.28 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	20 mg 2 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
36.98 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
37.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.54 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.6 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
9.89 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
9.35 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
11.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMORPHONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
20 mg 4 times / day multiple, oral Recommended Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15777102 Page: p.97	healthy, 27–44 n = 23 Health Status: healthy Age Group: 27–44 Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/15777102 Page: p.97	Disc. AE: Vomiting, Nausea... AEs leading to discontinuation/dose reduction: Vomiting (mild, 4.3%) Nausea (4.3%) Dizziness (4.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/15777102 Page: p.97
79.4 mg 1 times / day multiple, oral (mean) Highest studied dose Dose: 79.4 mg, 1 times / day Route: oral Route: multiple Dose: 79.4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15629415 Page: p.26	unhealthy, 45.5-47.5 n = 71 Health Status: unhealthy Condition: Back pain Age Group: 45.5-47.5 Sex: M+F Population Size: 71 Sources: https://pubmed.ncbi.nlm.nih.gov/15629415 Page: p.26	Disc. AE: Abdominal pain, Chest pain... AEs leading to discontinuation/dose reduction: Abdominal pain (1.4%) Chest pain (1.4%) Serum creatine phosphokinase increased (1.4%) Serum creatine phosphokinase MB increased (1.4%) Back pain (1.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/15629415 Page: p.26
0.5 mg 5 times / day multiple, intravenous Recommended Dose: 0.5 mg, 5 times / day Route: intravenous Route: multiple Dose: 0.5 mg, 5 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf Page: p.6	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf Page: p.6	Disc. AE: Opioid abuse, Respiratory depression... AEs leading to discontinuation/dose reduction: Opioid abuse Respiratory depression Addiction Hypotension (severe) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf Page: p.6
1.5 mg 5 times / day multiple, intramuscular\|subcutaneous (max) Recommended Dose: 1.5 mg, 5 times / day Route: intramuscular\|subcutaneous Route: multiple Dose: 1.5 mg, 5 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf Page: p.6	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf Page: p.6	Disc. AE: Opioid abuse, Respiratory depression... AEs leading to discontinuation/dose reduction: Opioid abuse Respiratory depression Addiction Hypotension (severe) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf Page: p.6
20 mg 5 times / day multiple, oral (max) Recommended Dose: 20 mg, 5 times / day Route: oral Route: multiple Dose: 20 mg, 5 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf Page: p.1	Disc. AE: Opioid abuse, Addiction... AEs leading to discontinuation/dose reduction: Opioid abuse Addiction Respiratory depression (grade 3-5) Withdrawal syndrome neonatal Anaphylaxis Hypotension (severe) Angioedema Hypersensitivity reaction Adrenal insufficiency Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf Page: p.1

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 768	inducer 383

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 450 18	CYP 450 31

Drug as perpetrator

Target	Modality	Activity
CYP 450 20	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201655lbl.pdf#page=19 Page: 19.0	no
CYP2C9 1803	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201655lbl.pdf#page=11 Page: 11.0	no
CYP3A4 1909	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201655lbl.pdf#page=11 Page: 11.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 450 31	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201655lbl.pdf#page=19 Page: 19.0	no

Sourcing

Vendor/Aggregator	ID	URL
AHH Chemical co.,ltd	MT-57608	http://www.ahhchemical.com/product/MT-57608.html
Alsachim	4226	http://www.alsachim.com/product-C5544-glo.bal-view.html
Ambinter	Amb22801505	http://www.ambinter.com/reference/22801505
Aurora Fine Chemicals LLC	A17.921.625	http://online.aurorafinechemicals.com/info?ID=A17.921.625
Avantor Inc	75835-940	https://us.vwr.com/store/product/21998648/exempted-drug-of-abuse-reference-standards-restek
BioCrick	BCC5255	http://www.biocrick.com/Oxymorphone-BCC5255.html
Chem Scene	CS-2852	http://www.chemscene.com/Oxymorphone.html
ChemMol	30105081	http://www.chemmol.com/chemmol/30105081.html
LGC Standards	LGCAMP0673.01-01	https://www.lgcstandards.com/US/en/p/LGCAMP0673.01-01
LGC Standards	LGCAMP0673.01-02	https://www.lgcstandards.com/US/en/p/LGCAMP0673.01-02
MedChem Express	HY-B0618	http://www.medchemexpress.com/Oxymorphone.html
Sigma-Aldrich	O-004_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/o004?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S619016	https://www.smolecule.com/products/s619016

PubMed

Title	Date	PubMed
Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids.	2005	16207320
Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets.	2005	15777102
Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis.	2005 Apr	15920941
Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial.	2005 Dec	16344024
Evaluation of induction by use of a combination of oxymorphone and diazepam or hydromorphone and diazepam and maintenance of anesthesia by use of isoflurane in dogs with experimentally induced hypovolemia.	2005 Jul	16111163
GC-MS quantitation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in blood.	2005 Jul-Aug	16105253
Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study.	2005 Mar-Apr	15767827
Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.	2005 May 5	15857143
Direct analysis of opiates in urine by liquid chromatography-tandem mass spectrometry.	2005 Oct	16419404
Evaluation of the DRI oxycodone immunoassay for the detection of oxycodone in urine.	2005 Oct	16419399
Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.	2005 Sep	16132361
Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.	2005 Sep-Oct	16266356
Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.	2006	16802855
Dissociative anaesthesia during field and hospital conditions for castration of colts.	2006	16722301
Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.	2006 Apr 4	16595013
Oxymorphone: a review.	2006 Feb	16317569
Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.	2006 Feb 16	16443205
Effects of oxymorphone and hydromorphone on the minimum alveolar concentration of isoflurane in dogs.	2006 Jan	16412134
A synthetic fraction of feline facial pheromones calms but does not reduce struggling in cats before venous catheterization.	2006 Jul	16764591
Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review.	2006 Jun 5	16705312
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.	2006 Mar	16750450
Comparison of an automated and point-of-care immunoassay to GC-MS for urine oxycodone testing in the clinical laboratory.	2006 Mar	16620541
Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.	2006 Mar	16291875
Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery.	2006 Mar 20	16343768
Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain.	2006 Mar-Apr	16513905
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.	2006 May	16678548
An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites.	2006 May	16541404
Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites.	2006 Oct	17132254
Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.	2006 Oct	17006080
Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.	2007 Apr 1	17098487
GC-MS analysis of multiply derivatized opioids in urine.	2007 Aug	17567826
Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and K(ATP) channels.	2007 Feb	17970197
Extended-duration agents for perioperative pain management.	2007 Feb	17214919
Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine.	2007 Feb	17211696
Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.	2007 Feb	17145204
Evidence that oxymorphone-induced increases in micronuclei occur secondary to hyperthermia.	2007 Feb	17077185
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.	2007 Jan	17257473
New pain management options: drugs.	2007 Jan	17198138
Oral oxymorphone (Opana).	2007 Jan 1	17179898
The effect of opiates on the activity of human placental aromatase/CYP19.	2007 Jan 15	17118343
Oral oxymorphone for pain management.	2007 Jul	17595308
Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.	2007 Jul 2	17383633
Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.	2007 Jun	17692717
Nociception increases during opioid infusion in opioid receptor triple knock-out mice.	2007 Jun 29	17544222
Oxymorphone hydrochloride, a potent opioid analgesic, is not carcinogenic in rats or mice.	2007 Mar	17138599
Two years follow-up study of the pain-relieving effect of gold bead implantation in dogs with hip-joint arthritis.	2007 Mar 23	17381835
Local peripheral antinociceptive effects of 14-O-methyloxymorphone derivatives in inflammatory and neuropathic pain in the rat.	2007 Mar 8	17204264
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base.	2007 May 30	17537266
Rapid analysis of metabolites and drugs of abuse from urine samples by desorption electrospray ionization-mass spectrometry.	2007 Sep	17710261
Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.	2008 Mar	17973932

Patents

Sample Use Guides

In Vivo Use Guide

Subcutaneous or Intramuscular administration: Initiate treatment with 1mg to 1.5 mg, every 4 to 6 hours. Intravenous Administration: 0.5 mg initially Oral: 10 to 20 mg every four to six hours.

Route of Administration: Other

In Vitro Use Guide

Oxymorphone hydrochloride was not mutagenic when tested in the in vitro bacterial reverse mutation assay (Ames test) at concentrations of ≤5270 ug/plate, or in an in vitro mammalian cell chromosome aberration assay performed with human peripheral blood lymphocytes at concentrations ≤5000 ug/mL with or without metabolic activation.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:43:42 UTC 2023` Edited by `admin` on `Wed Jul 05 23:43:42 UTC 2023`
Record UNII	9VXA968E0C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXYMORPHONE

Official Name

English

OXYMORPHONE CII [USP-RS]

Common Name

English

OXYCODONE HYDROCHLORIDE IMPURITY A [EP IMPURITY]

Common Name

English

4,5.ALPHA.-EPOXY-3,14-DIHYDROXY-17-METHYLMORPHINAN-6-ONE

Systematic Name

English

NIH 10323

Code

English

OXYMORPHONE [VANDF]

Common Name

English

OXYCODONE HYDROCHLORIDE IMPURITY, OXYMORPHONE- [USP IMPURITY]

Common Name

English

DIHYDROXYMORPHINONE

Common Name

English

IDS-NO-003

Code

English

MORPHINAN-6-ONE, 4,5-EPOXY-3,14-DIHYDROXY-17-METHYL-

Systematic Name

English

14-HYDROXYDIHYDROMORPHINONE

Common Name

English

oxymorphone [INN]

Common Name

English

OXYMORPHONE CII

Common Name

English

7,8-DIHYDRO-14-HYDROXYMORPHINONE

Common Name

English

Oxymorphone [WHO-DD]

Common Name

English

OXYMORPHONE [MI]

Common Name

English

NSC-19045

Code

English

Classification Tree Code System Code

NDF-RT

N0000175690